
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 18, 2026
Meiji reports a 7.88% beneficial interest in Arcturus
Nasdaq: $ARCTRare disease therapeuticsMeiji placement closedPivotal evidence still ahead
ARCT Stock Hub: Arcturus Therapeutics News, Meiji and Rare Disease Trials
Meiji’s $50 million equity investment gives Arcturus more room to test its rare-disease drugs. The test is whether longer cystic fibrosis follow-up and separate human data in OTC deficiency justify the next major spending decision. September cash and equivalents were $184.8 million, before the placement; most of that quarter’s revenue came from unwinding the CSL Seqirus deal, rather than a durable new sales stream. The Meiji filing also sets a May 2027 deadline that could require a partial refund.
Full research report · PDF
ARCT research report · November 21, 2026
20 pages · Clinical evidence, the Meiji placement and refund, quarterly accounts, financing and ownership. For personal use only: redistribution prohibited.
Next clinical catalyst · company target
ARCT-032 Cohort 4 enrollment completion · exact date not announced
Arcturus expects enrollment to finish by year-end 2026. It plans to present the cohort’s data in the second quarter of 2027 and expects to decide whether to proceed to Phase 3 before the presentation. November 5 pipeline update
Dated contract trigger: May 31, 2027 is the deadline for the definitive Japan license contemplated by the Meiji memorandum. November 16 Form 8-K
ARCT stock at a glance
Where Arcturus stands now
Cash and evidence are moving on different schedules. The November investment is a closed transaction. The full ARCT-032 Cohort 4 data and the first ARCT-2601 human data are still ahead. There is no September-quarter sales run rate that captures the new company after the CSL settlement.
Constructive · Financial room to test two programs
Management can fund early follow-up and still decide where a controlled trial makes sense. A clearer result in one program would help reserve resources for the study that can answer the most consequential clinical question.
Cautious · A larger trial is a new funding decision
Loss of a former revenue contributor and more intensive clinical work can pull in opposite directions from the reported quarter. Later spending will depend on the evidence and which costs partners actually cover.
Latest ARCT news
Nov 18, 2026
Meiji reports a 7.88% beneficial interest in Arcturus
Meiji reported beneficial ownership of 2,466,395 common shares for its November 16 event date. The filing used an enlarged denominator of 31,288,909 shares.
Nov 16, 2026
Arcturus closes $50 million Meiji strategic placement
Arcturus issued 2,466,395 shares to Meiji at closing. If the definitive Japan license contemplated by their memorandum is not signed by May 31, 2027, the purchase agreement requires a refund of approximately $11.1 million.
Nov 13, 2026
Amova Americas reports September 30 Arcturus ownership
Amova Asset Management Americas reported beneficial ownership of 1,689,107 shares, or 5.9% of the class, and shared voting power over 1,459,991 shares.
Nov 5, 2026
Arcturus Therapeutics announces third quarter 2026 financial results and pipeline progress
Arcturus reported a net loss of $7.4 million and revenue of $18.3 million for the three months ended September 30, 2026. Cash and cash equivalents were $184.8 million as of September 30, 2026. ARCT-032 (CF) Phase 2 full data from Cohort 4 are planned for presentation in Q2 2027, and Phase 2 dosing of ARCT-2601 is planned to begin in Q1 2027, with top-line data expected in H2 2027.
Oct 29, 2026
Sumitomo Mitsui and Amova report shared Arcturus holdings
Sumitomo Mitsui Trust Group and Amova Asset Management reported shared voting and dispositive power over the same 1,689,107 shares, or 5.9%, as of September 30.
Oct 15, 2026
Arcturus completes the myNEO acquisition
Arcturus paid approximately $5 million in cash and issued 361,355 common shares at closing. The November 5 quarterly filing also describes up to $20 million of contingent payments.
ARCT catalyst calendar
- November 5, 2026Reported — September earnings and pipeline update.
- November 16, 2026Closed — Meiji placement and related agreements.
- By year-end 2026Company target — ARCT-032 Cohort 4 enrollment completion.
- First quarter 2027Company plan — First ARCT-2601 dosing under an amended Phase 2 protocol; no day announced.
- Before the planned CF data presentationCompany expectation — Decision on whether to advance ARCT-032 to Phase 3. November 5 update.
- Second quarter 2027Company target — Cohort 4 results presentation.
- May 31, 2027Contract deadline — Deadline to sign the definitive license contemplated by the memorandum or trigger a conditional refund.
- Second half of 2027Company target — ARCT-2601 topline and separate phenylketonuria IND goal.
Two clinical programs and a commercial transition
Cystic fibrosis
ARCT-032
Open-label Phase 2 in adults not taking a modulator. The longer cohort tests whether earlier observations are consistent and tolerability holds with longer follow-up.
OTC deficiency
ARCT-810 and ARCT-2601
The ARCT-810 interim biomarker findings frame an early study of a different investigational candidate. ARCT-2601 needs its own human findings.
Country-specific
KOSTAIVE
EU authorization and ongoing seasonal commercialization in Japan are separate from the rare-disease trials and their regulatory pathways.
Arcturus Therapeutics deep dive: the full analysis
What the new financing buys, what the two clinical programs can show, and where their costs appear in the accounts. The Merlintrader Research Library collects our dated biotech stock research reports.
01Three paths from partner capital to patient evidence
Arcturus enters the next set of human studies with an unusual combination: a closed strategic equity investment, an authorized vaccine whose old commercial arrangement is winding down, and two investigational treatments whose next evidentiary steps differ. The capital makes it easier to run the studies. It does not make either study easier to interpret. The strongest case for ARCT is therefore about what the company can learn with the money already raised, rather than what a strategic investor might know about results that have not arrived.
Bull case · Two trials earn a next step
The longer cystic fibrosis cohort produces a lung-function or symptom signal across enough participants to define a credible controlled study. Separately, ARCT-2601 provides interpretable human safety and biomarker data in ornithine transcarbamylase deficiency. The Thermo Fisher arrangement reduces qualifying costs in a program worth advancing, and Meiji and Arcturus sign the definitive Japan agreement by its contractual deadline.
Bear case · Timelines advance faster than the evidence
Enrollment and readouts slip or produce heterogeneous results. A signal appears principally in exploratory measures, or adverse events make longer exposure harder to justify. A refund under the Meiji contract, rising trial costs, or the weaker contribution from legacy collaborations then compresses the budget for the next controlled test.
Base case · A financed transition, with the expensive decision still ahead
One or both programs can progress without demonstrating a registrational benefit in 2027. A coherent Phase 2 package could narrow the range of endpoints, follow-up periods, and patient groups worth studying. It could also expose an important mismatch: a response that looks promising over a short observation window may be too variable to justify an expensive pivotal design. A base case gives the studies time to answer those questions. It does not count a later trial as funded simply because the current trials look financeable.
These paths can diverge within one report. A clearer biological signal might coincide with a slower schedule, or a good enrollment update with an inconclusive safety picture. In the first case, the evidentiary case could improve as the timeline stretches; in the second, an on-time milestone could do little for the odds of a successful next trial. The November disclosures put identifiable dates and contractual terms around that uncertainty, without turning clinical development into one binary event. See the November 5 pipeline update and the November 16 transaction filing.
What would falsify this reading?
- A preplanned and clinically important CF signal accompanied by a credible, funded controlled-study plan would make the description of CF as predominantly exploratory too conservative.
- If neither program generates an interpretable set of repeat-exposure data and Arcturus cuts spending before a confirmatory decision, the capital available in November would have bought less useful evidence than the base case assumes.
- If reported cash collections from the reorganized commercial portfolio become material and recur across reporting periods, the post-CSL revenue argument changes. A single payment or a balance-sheet reclassification cannot answer that question on its own.
- If positive OTC biomarker findings repeatedly coincide with safety-driven discontinuations, the case that a cleaner delivery platform can improve the treatment proposition would need to be rebuilt around tolerability, not just activity.
02What Arcturus does and what now pays for it
Arcturus Therapeutics Holdings develops messenger RNA medicines. Its leading rare-disease programs aim at different deficits: ARCT-032 is an investigational treatment for cystic fibrosis and ARCT-810 and ARCT-2601 are investigational treatments for ornithine transcarbamylase deficiency. The company also has a vaccine business, including KOSTAIVE, with country-specific commercial and regulatory positions. Arcturus consolidates these activities into a single reporting segment. Segment figures therefore describe spending by category, but they cannot be read as stand-alone financial accounts for respiratory, liver, and vaccine franchises. The company describes the segment and its cost categories in September Form 10-Q, Note 9 and MD&A.
The therapeutic opportunity is easier to define than the sales opportunity. In CF, ARCT-032 is initially being studied in adults who are not taking current modulators. In OTC deficiency, the question is whether an investigational treatment can improve metabolic management on top of the care patients already receive. A positive study in one setting would not quantify the probability of benefit in the other. Different organs, baseline risks, clinical measurements, and patient populations put different demands on the evidence. That is why the two programs are better judged separately than pooled into a single platform narrative.
Nor should the commercial history of KOSTAIVE be treated as a proxy for rare-disease revenue. A licensed product can generate royalties or contractual revenue in a defined territory without providing clinical precedent for a different medicine. Conversely, a rare-disease study can be productive even if future vaccine receipts are modest. What connects those activities is a common cash budget. Depending on when partner receipts arrive and how many studies Arcturus decides to advance, clinical spending can rise sooner than commercial contributions. The 10-Q’s revenue and funding disclosures show the cash and obligations that actually pass through that budget.
The roles of the two newer counterparties clarify the business model. Meiji took an equity stake and has commercial and licensing relationships with the company. Thermo Fisher supplies or agrees to support defined categories of work for one development program. Neither relationship is a whole-company commitment to pay Arcturus’s operating costs. A partner can have a rational reason to participate without endorsing every asset in the portfolio. A meaningful increase in the value of either relationship would be visible through a new binding term, the first use of a service commitment, a disclosed commercial payment, or another development decision with a practical consequence.
Joseph Payne, president and chief executive officer, described the investment proceeds as supporting ARCT-2601 in the November 16 release. That use of proceeds ties the financing story to a specific proof-of-concept question. It also leaves a trade-off: if CF advances and OTC development accelerates around the same period, the company can no longer assume that recent spending reflects the future pace. In a small clinical company, the cost of a better opportunity can rise precisely when the evidence improves, because the larger studies needed to substantiate the opportunity cost more.
03ARCT stock catalysts: track the decision behind each date
Enrollment in the fourth CF cohort is the nearer operating milestone. Completion would answer whether Arcturus reached the group it intended to study, not whether the group benefited. The company said in its November 5 update that enrollment was expected to finish by year-end 2026, with data planned for the second quarter of 2027. It separately expected a decision about advancing to Phase 3 before that presentation. That ordering matters: a commitment to a later trial and the release of results to outsiders can occur in a different sequence, and the decision itself cannot substitute for the actual data.
A company can make a Phase 3 decision for several reasons: sufficiently persuasive efficacy to justify a larger test, a manageable safety profile plus a narrowing set of endpoints, financing that makes a well-designed trial possible, or a combination of those factors. A decision to advance tells readers that management believes the next trial is worth doing. A description of the proposed population, comparator, duration, and clinical outcomes tells them what the next trial can prove. A Phase 3 heading with no particulars is evidence of intent, not a measure of the probability of success.
The ARCT-2601 sequence separates entry into human evaluation from the first results. In its September 23 release, Arcturus expected dosing to begin near year-end 2026. The November 5 disclosure moved the planned start to the first quarter of 2027 and targeted topline data for the second half of 2027. Arcturus has not named a calendar day for dosing or for the data presentation. The Phase 2 timetable is especially sensitive to the number of eligible participants, whether follow-up is complete, and which observations the company chooses to include in the first release.
May 31, 2027 is different from the clinical windows. It is a calendar date in a binding securities purchase agreement. Its importance is the potential refund resulting from failure to sign a definitive agreement contemplated by the Japan memorandum, not an expectation that the vaccine business or the OTC program will deliver a result that day. The November 16 8-K specifies the trigger. A prior signature may resolve that particular downside before the deadline; a lack of disclosure before May does not by itself show that negotiations have failed. The financial consequences and possible settlement routes are in the Meiji chapter.
What could shift the investment analysis ahead of those windows is a change that travels through more than one statement: an amended study scope tied to a funding decision, a partner contribution that appears in recognized expenses or cash flows, or a clinical package that specifies the analysis population and the safety denominator. Conference participation alone changes none of those. That distinction also keeps a timing change in perspective. Moving a presentation can be administrative; moving a trial because eligible patients cannot be recruited can affect the eventual choice of comparator or the ability to produce convincing results.
04ARCT-032: who is in the cystic fibrosis study?
Cystic fibrosis is caused by variants in the cystic fibrosis transmembrane conductance regulator gene, usually abbreviated CFTR. A therapy that improves the function of existing CFTR protein has a different clinical proposition from one intended to supply a missing function. Several modulators have transformed care for eligible patients; the gap is narrower and more complex than the entire CF population. In Middleton et al., New England Journal of Medicine, 2019, 403 patients with one Phe508del allele and one minimal-function allele received either a triple combination or placebo in a randomized trial. The difference in percent predicted forced expiratory volume in one second, or ppFEV1, was 13.8 percentage points at week four. Exacerbations and respiratory quality of life also improved. The trial established an effect in the studied genotype, not in patients with two variants that make available modulators ineffective.
Even within the group without an F508del allele, modulator response cannot be inferred from the absence of that allele alone. In Castellani et al., American Journal of Respiratory and Critical Care Medicine, 2026, a randomized trial reported a 9.2-percentage-point treatment difference in ppFEV1 in people selected for particular rare responsive variants and without F508del. The selection is the point: the results expand the evidence for certain variants without showing that all rare variants are treatable. Separately, the two large active-controlled SKYLINE studies in Keating et al., Lancet Respiratory Medicine, 2025 tested one triple regimen against another and found noninferiority on their specified lung-function comparison. Those studies show the sophistication of the established market, but neither tested ARCT-032 or provides a direct benchmark for an untreated Class I-enriched cohort.
The LunairCF registry record, NCT06747858, describes a Phase 2, open-label trial in adults who are not receiving modulator therapy. That description can encompass people with ineligible variants and people who are off modulators because of intolerance, poor response, or access. These are different clinical and commercial situations. For an ineligible patient, a successful therapy might address a sustained gap. For a person not taking an otherwise suitable modulator because of access, the gap can change independently of ARCT-032’s effectiveness. Treating the entire study population as if it has the same treatment alternatives would overstate what can be learned about eventual prescribing.
The November update describes Cohort 4 as up to 20 adults, primarily with Class I disease, and a 12-week treatment period. The registry’s estimated enrollment of 33 refers to the full study, not this cohort. The registry places adverse events at the center of the assessment; spirometry, symptoms, and imaging can help characterize activity. The September 10-Q’s business update says enrollment and dosing had been completed in the initial three cohorts and attributes faster Cohort 4 enrollment to additional active sites. Faster site activation improves the odds of obtaining the cohort. It tells readers little about the distribution of responses or whether missing measurements cluster among participants who discontinued treatment.
An open-label design can establish whether a longer course is feasible and reveal recurrent events worth monitoring. It is less able to assign a change in symptoms or lung function to therapy when background treatment, respiratory infections, baseline variability, and expectations may change during the observation period. A cohort drawn from several countries can broaden recruitment yet still be small enough that a few participants drive the mean. At the readout, the useful details will be whether all treated patients are included in the appropriate safety denominator, how many completed follow-up, and whether the direction of the result is consistent across more than one clinical measure.
Outside Arcturus, there is already a human example that argues against assuming an inhaled RNA medicine will improve spirometry simply because the approach is plausible. Rowe et al., Journal of Cystic Fibrosis, 2023, reported interim results in 42 adults in the randomized MRT5005 study. They observed no consistent benefit on FEV1 and reported febrile and hypersensitivity reactions in a subset. MRT5005 and ARCT-032 are different candidates. The study offers a clinical caution about assigning a class-wide effect; it does not predict whether ARCT-032 will succeed or which adverse events it will produce.
05CF endpoints: why the imaging and spirometry findings differ
In its October 22, 2025 interim release, Arcturus reported that mucus plug count and volume fell in four of six adults with Class I CF in the second cohort. The initial comparison of spirometry from Day 1 to Day 28 did not show a meaningful improvement. A later exploratory comparison used a different baseline and a later measurement and suggested improvement in four participants. Those findings can coexist: imaging and airflow measure different aspects of disease, and changing the analysis window can change the apparent signal. The later comparison is less persuasive as evidence of efficacy because it was selected after seeing data, not because it is impossible for a later effect to exist.
What can an imaging result earn? It can identify a hypothesis for a longer and better controlled test. It helps if the full cohort is shown, rather than a gallery of apparent responders; the company’s earlier table included people whose measures worsened as well as those whose measures improved. Durable clinical value would require a result that remains interpretable in the presence of that variability. An observed change in a lung image is accordingly useful alongside serial spirometry, patient experiences, and measures of whether participants remain on therapy. Standing alone, the image does not show fewer exacerbations, less time in hospital, or a slower decline in lung function.
Lung clearance index, or LCI, adds a measurement of how evenly the lungs ventilate. It need not move in lockstep with conventional spirometry. In the observational RECOVER study, McNally et al., American Journal of Respiratory and Critical Care Medicine, 2023 followed people starting elexacaftor/tezacaftor/ivacaftor, finding improvements in LCI, spirometry, and several computed tomography measures. The study illustrates the kinds of convergence a disease-modifying therapy can produce, but it studied people with relevant F508del genotypes receiving an approved modulator, rather than the population enrolled by Arcturus. Neither its numerical effects nor the changes in individual imaging measures are targets for LunairCF.
The September 2026 10-Q reports two serious adverse events after the treatment period across the initial cohorts that the company described as unrelated to ARCT-032. The October 2025 release had described one serious event in the second cohort, and said the monitoring committee found no convincing evidence that it was related. The time windows and populations are different; adding the release event to the later overview as a third would count beyond what the filings show. The larger safety question is how many people tolerate the longer period of treatment, whether events cause discontinuation, and whether the event profile changes over time.
There is a difference between a safety finding that supports another trial and a safety profile established for sustained use. A later-stage study will need a population that can stay on background care, a comparator that addresses natural variability, and enough follow-up to make changes in symptoms meaningful. Positive signals in imaging and LCI without movement in ppFEV1 would not automatically end development. They would make the choice of primary endpoint and comparator critical. An apparent spirometry effect concentrated in one or two participants, without concordant outcomes or with uneven follow-up, would be harder to translate into a pivotal design.
Commercial interpretation should come last. The relevant overlap is among patients with a documented unmet need, patients eligible for the eventual label, and patients who can realistically receive the treatment as used in a care setting. An early study can inform the first two pieces by showing which groups are eligible and where effects appear. It cannot settle uptake, reimbursement, or persistence. The difference matters when assessing what Thermo Fisher’s support is worth: a well-run late-stage trial may become cheaper to execute under qualifying terms, but the economics will only matter if the clinical case warrants running it.
06OTC deficiency: the clinical meaning of the ammonia signal
Ornithine transcarbamylase deficiency is an inherited disorder that impairs disposal of nitrogen and can cause hyperammonemia. The clinically relevant question is whether people can avoid serious episodes and maintain safe metabolic control through daily life, including periods of illness and changing nutritional demands. Standard management can include dietary management and nitrogen scavengers; transplantation is an option for some patients. Decisions vary with severity, age at presentation, and prior events. Historical care is therefore a source of context, not a single placebo course against which an open-label study can be compared. See Brassier et al., Orphanet Journal of Rare Diseases, 2015 and Batshaw et al., Molecular Genetics and Metabolism, 2014.
Batshaw and colleagues described 614 participants spanning eight urea cycle disorders, with OTC deficiency the most common. Their observations about late presentation, clinical triggers, and associated neurologic risks explain why the size of the population with measurable ammonia changes is only part of the problem. Brassier and colleagues studied 90 patients with OTC deficiency over a long period at one center. Outcomes varied sharply with presentation, and severe decompensation could occur even in those presenting as adults. A group of relatively stable adolescents and adults in a study can differ from neonates or patients with severe late-onset disease on more dimensions than age. A favorable average in one group cannot be transferred to the others without data.
Even for patients in the same age group, the measurement chosen changes the inference. Díaz et al., Hepatology, 2013, used 24-hour ammonia exposure in the pivotal adult comparison of glycerol and sodium phenylbutyrate. Glycerol phenylbutyrate was noninferior on that measure. Berry et al., Molecular Genetics and Metabolism, 2014, examined pediatric data including ammonia exposure and longer-term outcomes. Differences in their pooled short-term measures and observations in open-label extensions answer different questions; the former can characterize metabolic control over short periods while the latter are more vulnerable to differences in care over time. For Arcturus, fasting ammonia and glutamine are meaningful early signals, but neither is equivalent to a controlled demonstration of fewer hyperammonemic crises or durable clinical benefit.
The September 23 company release and the September 10-Q describe interim results from the open-label U.S. study. The September 23 presentation, slides 8–11, reports eight participants in the safety analysis and seven in the biomarker analyses, based on biomarker data available September 11, 2026. Arcturus reported that fasting morning ammonia fell or remained within the normal range, including during periods of increased protein intake, and that glutamine declined; the higher-dose cohort’s mean was within the normal range during treatment. The circulating measurements are part of a coherent biological observation. They come from a small uncontrolled group and an interim disclosure. The useful question is how the patterns hold up across individuals and time, not whether every favorable finding can be made into a different efficacy claim.
The 10-Q states there were no serious adverse events in that U.S. interim discussion; it also reports two Grade 3 non-serious asymptomatic liver enzyme elevations that resolved after treatment stopped, and one participant who discontinued after one treatment because of a non-serious adverse event. Severity grade and regulatory seriousness have different definitions. A non-serious event may still matter for repeat exposure or for an individual patient’s ability to stay in a trial. The filing does not justify adding the reports to infer that three distinct participants were affected. The U.S. registry record, NCT06488313, predates the November operational update; the separate randomized study, NCT05526066, enrolled eight in Europe and the United Kingdom and was stopped after the first cohort because of slow enrollment. Those are two different sets of eight, not one data set with a placebo comparison.
ARCT-2601 is the next clinical test, not a restatement of the ARCT-810 findings. Management described advice from a June 2026 Type C meeting with the FDA and its plan to include the new candidate in an amended Phase 2 protocol. The new program can use what was learned about suitable patients and relevant measures. It still needs its own human evidence: repeat exposure, a tolerability profile, and biomarker changes that can be interpreted in the context of stable care. Evidence from animals cannot establish a human treatment effect or the frequency that will be acceptable in practice. Neither the regulatory discussion nor the financing creates an approved therapy. November 5 Exhibit 99.1 sets out the program and timing.
07ARCT earnings: the September quarter and the CSL exit
The September quarter showed a smaller loss and higher revenue than the same quarter of 2025. The nine-month statements showed a larger loss and much lower revenue. Both comparisons are accurate. The third-quarter improvement captures a settlement with a former partner and lower spending, while the year-to-date comparison captures the fading contribution of that collaboration. The November 5 Form 10-Q, statement of operations and Note 2, reconciles the two views. The figures below are in millions of U.S. dollars, except per-share amounts.
| US$ million except per share | Q3 2026 | Q3 2025 | 9M 2026 | 9M 2025 |
|---|---|---|---|---|
| Collaboration revenue | 16.852 | 14.153 | 18.342 | 64.140 |
| Grant revenue | 1.445 | 2.998 | 4.975 | 10.695 |
| Total revenue | 18.297 | 17.151 | 23.317 | 74.835 |
| Research and development, net | 16.998 | 23.265 | 56.040 | 87.736 |
| General and administrative | 10.484 | 10.398 | 30.938 | 32.052 |
| Total operating expenses | 27.482 | 33.663 | 86.978 | 119.788 |
| Operating loss | (9.185) | (16.512) | (63.661) | (44.953) |
| Finance income, net | 1.773 | 3.234 | 5.524 | 8.572 |
| Other expense | (0.002) | (0.170) | (0.026) | (0.319) |
| Income tax expense | 0 | 0 | 0 | 0.004 |
| Net loss | (7.414) | (13.448) | (58.163) | (36.704) |
| Basic and diluted loss per share | (0.26) | (0.49) | (2.05) | (1.35) |
CSL Seqirus accounted for $16.814 million of the $18.297 million in third-quarter revenue. Under the August 3 termination and settlement agreement, Arcturus received a one-time $12.0 million cash payment. It also recognized $5.2 million of remaining deferred revenue when the relevant performance obligations ended, offset by about $0.4 million of previously recognized amounts that would not be collected. The rounded components reconcile to about $16.8 million. The approximately $16 million of released obligations had a different meaning: it represented relief from an R&D credit and repayment of unspent development payments. It was not another cash receipt on top of the $12 million.
The residual $1.483 million of revenue consisted of grants and a small contribution from other collaborators. Merlintrader calculation: subtracting the CSL line isolates the reported contribution of the remaining categories, not a forecast of future revenue. Grants can vary with eligible costs and reporting. Total deferred revenue fell from $8.246 million at year-end 2025 to $419,000 at September 30, and the September balance had no CSL component. A release of deferred revenue can lift a quarter’s income statement without an equivalent new inflow; a smaller residual deferred balance also reduces what can be recognized from the same pool in later quarters. See Note 2 and the contract balance rollforward.
The change in spending was not uniform. Note 9 reports lower vaccine-program R&D, payroll and benefits, and facilities and equipment expense compared with the year-earlier third quarter. The allocated OTC line moved in the opposite direction, rising from $780,000 to $3.073 million. Cystic fibrosis is shown net of qualifying offsets; the program line also excludes shared categories listed separately. It would be misleading to use that line alone as an all-in trial budget. General and administrative costs were almost flat in the quarter, and net finance income was lower. The resulting quarter looks less expensive as a whole while the priority programs are already drawing resources.
The arbitration related to an EU approval milestone, not to the safety or efficacy of the product. The 10-Q says the International Chamber of Commerce tribunal acknowledged dismissal on August 5 after the settlement and mutual releases. The dismissal followed a negotiated settlement rather than a disclosed merits award. The legal release narrowed one source of uncertainty but did not recreate the former milestone stream. The forward question is what the new commercial arrangements contribute after the transition, without assigning a value to that future contribution before it is disclosed.
Separate litigation remains relevant to legal spending and execution. In its 10-Q, Part II, Item 1, Arcturus says it filed a trade-secret and contract suit against AbbVie, Capstan and other defendants on September 23, 2025, in the U.S. District Court for the Southern District of California, case 3:25-cv-02494. The company filed an amended complaint April 13, 2026; Capstan asserted counterclaims in May, and Arcturus answered in June. The court’s November 3 case-management order addressed discovery confidentiality, not the merits. The filing reports no trial date. These are disputed claims, not established findings or a measurable future recovery.
08Cash runway, lease obligations, and the cost of another study
At September 30, Arcturus reported $184.817 million in cash and equivalents available apart from $2.028 million of restricted cash. The restriction supports property leases. The cash-flow statement presents both together, for $186.845 million; the smaller balance is the relevant starting point for operating resources. The balance sheet did not list a separate investment securities line. Note 3 describes cash equivalents and money-market funds as the assets remeasured at fair value on a recurring basis. Counting them again on top of the reported cash line would overstate available liquidity. See balance sheets, cash-flow statement and Notes 3 and 4.
| US$ million | 2026 | 2025 |
|---|---|---|
| Cash and restricted cash at start | 232.794 | 293.913 |
| Net operating cash use | (46.256) | (58.044) |
| Net investing cash use | 0 | (0.318) |
| Net financing cash provided | 0.307 | 1.694 |
| Cash and restricted cash at end | 186.845 | 237.245 |
Merlintrader calculation: the cumulative nine-month operating cash use less $39.351 million in the June 10-Q’s six-month statement implies $6.905 million of operating use in the September quarter. If the $12 million CSL receipt had not arrived, all else equal, third-quarter operating cash use would have been $18.905 million, and nine-month use would have been $58.256 million. The adjusted figures isolate the receipt; they do not erase other changes in working capital and should not be treated as a projected rate. Collections, vendor payments and accruals still matter. Even compensation recorded as expense has a different effect on cash when it is paid in equity.
The change in cash reconciles without a financing draw. Equipment purchases and disposals each amounted to $52,000 over the nine months, resulting in zero net investing flow. Financing contributed $307,000, from stock option exercises and stock issued under equity plans. The $45.949 million net cash decline includes restricted cash. The unrestricted balance fell $46.092 million, from $230.909 million at December 31, 2025, while restricted cash rose by $143,000. The two numbers are consistent, rather than alternate estimates of burn.
The 10-Q contains no funded-debt line at September 30 or debt proceeds or repayments in the first nine months of 2026. The former Wells Fargo revolving credit and security agreements ended in December 2025; the $55 million of pledged cash still classified as restricted in September 2025 does not recur in the September 2026 balance. It would be wrong to count the old credit line as a fallback or attach its covenants to current liabilities. Operating leases remain. Note 8 reconciles $25.030 million of scheduled payments to $21.865 million of recorded lease liabilities after $3.165 million of imputed interest. Of the carrying amount, $3.621 million was in accrued current liabilities and $18.244 million was noncurrent. No funded-debt leverage covenant is presented in the September statements. 2025 Form 10-K · September 10-Q, Notes 4 and 8.
The 10-Q said available cash should cover at least the next 12 months, subject to continued funding and no significant unforeseen costs, and that the company expects to need additional capital for its long-term plans. In the same day’s earnings release, Chief Financial Officer Dennis Mulroy gave an operating runway estimate through year-end 2028. The two disclosures have different purposes: one sets a minimum horizon subject to conditions and one conveys a longer management planning horizon. Neither provides a quarterly projection. They also precede the Meiji transaction. Adding the transaction amount to the September cash line would leave out October and November operations, the myNEO closing, deal expenses if applicable and future contingencies. The next set of statements is the appropriate place to reconcile those cash movements.
What matters for the outlook is the marginal cost of clinical progress. A higher cash balance can give the company more time to decide between alternatives, but extending a development plan can add substantial spend before any new sales. Two possibilities deserve separate attention: a weak readout can make further spending hard to justify; a strong readout can make a larger commitment necessary before new receipts appear. A runway estimate can shorten in either situation. The expected duration of cash and the ability to finance a full program are different questions.
09Meiji’s equity investment, refund trigger, and commercial rights
The November 16 Form 8-K, Items 1.01 and 3.02, says Arcturus sold Meiji Seika Pharma 2,466,395 unregistered common shares for an aggregate $50.0 million, and that closing occurred concurrently with signing. The company’s Exhibit 99.1 specifies a contract price of $20.27 per share. The stock sale financed Arcturus; it was not a secondary transfer between shareholders. The same filing describes a conditional refund tied to a separate negotiation, a distinct executed license, and rights that affect the handling and eventual resale of the shares.
| Term | Status | What follows |
|---|---|---|
| Common-stock placement | Closed November 16 | New shares and $50.0 million gross consideration |
| Definitive Japan preparedness license | Nonbinding memorandum | Approximately $11.1 million refundable if not signed by May 31, 2027 |
| Separate exclusive license | Executed November 16 | Undisclosed therapeutic area; Meiji responsible for development and commercialization at its cost |
| Transfer and standstill | Binding, subject to exceptions | 365-day transfer restriction; 24-month standstill and participation provisions subject to a 9.9% ownership limit |
| Registration rights | Binding commitment | Resale registration for issued shares, not a second financing |
The refund becomes payable if the definitive license contemplated by the nonbinding memorandum is not executed by the deadline. It equals half the contract premium, approximately $11.1 million. Arcturus can pay in cash or elect to settle in common shares subject to limitations. In a cash-settlement illustration, $50.0 million less $11.1 million leaves about $38.9 million of original gross proceeds before fees and any other cash movement. That calculation is a way to separate gross proceeds from one contingent outflow. It is neither a prediction that the refund will occur nor a net balance-sheet update. A share settlement would preserve cash at the cost of additional issuance, on terms that should be read from the relevant disclosure if it happens.
The standstill provision and the restrictions on transfer serve different purposes. The ownership cap limits certain acquisitions and future participation for the stated term; the transfer provision restricts disposition of these shares through the 365th day, subject to customary exceptions. The resale registration commitment operates alongside those provisions. The filing deadline is the earlier of the 180th day after closing or the 30th day following certain early releases from the transfer restrictions. A resale registration does not place cash in Arcturus’s account, and its filing does not itself show that Meiji has disposed of shares. Later holdings disclosures would be the evidence for that separate question.
Meiji’s stake can stabilize a commercial relationship and improve financing flexibility while creating meaningful concentration in a single counterparty. The Japanese seasonal distribution arrangements, the executed license in an undisclosed therapeutic area, the nonbinding preparedness memorandum, and Meiji’s stock ownership should be followed as four distinct relationships. Progress on one is not evidence that the others deliver specific economics. An eventual binding agreement could make the partnership broader; until its financial terms are disclosed, the absence of the refund is the measurable part of the existing contract.
The logic of the deal is clearest when the funding and the science are kept apart. An investor may accept a contract premium for reasons that involve strategic access, governance restraints, and commercial optionality. None of those terms measures human response to ARCT-2601. The transaction supports an operating plan in a way that can be measured. Its clinical value depends on what the proposed study can demonstrate with that support.
10ARCT share dilution: issued stock, capacity, and awards
The September balance sheet reports 28.461 million issued and outstanding common shares, rounded in thousands. The November 5 10-Q’s cover reports 28,822,514 outstanding as of November 3. The myNEO acquisition closed October 15, before the cover-page count. Note 11 records approximately $5 million in cash and 361,355 unregistered shares at closing, with base consideration of $10 million subject to adjustments. Adding those shares again to the November 3 cover would overstate the known share base. The same note identifies potential contingent milestone and collaboration payments capped at $20 million, certain of which may be settled in stock. Those commitments are separate from the shares already issued. 10-Q cover, equity statement and Note 11.
Adding the Meiji issuance to the November 3 figure produces 31,288,909 shares, the denominator Meiji used in its Schedule 13G. The new shares increased that pre-deal reference base by approximately 8.56%; measured as a share of the enlarged denominator, they represent 7.88%. These calculations use two different denominators and describe the same transaction. The higher percentage is the increase in count, not Meiji’s ownership. Nor is the enlarged denominator a fresh, company-certified daily share count: it is the September filing’s November 3 figure plus the disclosed issuance.
An at-the-market equity agreement, or ATM, creates a different exposure. Note 5 states a $200 million nominal aggregate sales limit and discloses December 2025 sales of 1,179,201 shares for about $12.2 million gross and $11.7 million net. The 2025 Form 10-K says those were the aggregate sales under the agreement as of that filing. The September 2026 10-Q says there were no sales under the program through the first nine months of 2026. Using the reported gross total, the arithmetic headroom is about $187.8 million at that point, before practical and legal constraints. It is not unrestricted financing, committed equity proceeds, or a claim that no later transactions have occurred. An undrawn agreement changes financing choices; only execution changes ownership and cash. 2025 10-K, Risk Factors · September 10-Q, Note 5.
Equity awards require another distinction. At September 30, the balance available for future issuance under the 2019 Omnibus Equity Incentive Plan was 1,095,640 shares; the inducement plan disclosed 188,926 available. These are plan reserves, not outstanding option or restricted stock unit counts. For a dated comparison, the 2025 Form 10-K, Note 9, reported 8,868,607 options outstanding at December 31, 2025, of which 6,046,218 were exercisable. It also reported 18,786 outstanding restricted stock units that had vested but whose release was subject to specified conditions. Those year-end counts are a historical benchmark, not September 2026 quantities. Options are rights to acquire shares on specified terms; restricted stock units generally settle after applicable conditions are met. Share-based expense of $12.598 million for the first nine months was recognized in R&D and G&A, but was added back in the cash-flow reconciliation. Share issuance on exercise or a plan settlement is a separate event. September 10-Q, equity statement and Note 6.
The quarter and nine-month loss-per-share notes exclude 0.2 million and 0.1 million potentially dilutive shares, respectively, as antidilutive for those reporting periods. Those are per-period earnings-per-share calculations, not a list of all options and units outstanding. The September filing does not furnish an updated complete award rollforward by class or identify funded convertible debt or financing warrants outstanding. It would be unsound to equate accounting exclusions with the maximum number of shares that might eventually be issued. The concrete dilution channels are already separable: issued Meiji and myNEO stock, possible future ATM activity, vesting and settlement of compensation, and conditional consideration or refunds that may be paid in equity.
11Thermo Fisher, the Cystic Fibrosis Foundation, and the next spending step
Arcturus’s June 26 collaboration with Thermo Fisher addresses two different cost categories. Thermo Fisher agreed to contribute up to $40 million in qualifying clinical manufacturing services. If Arcturus advances ARCT-032 to Phase 3, it has agreed to engage PPD for up to $40 million in qualifying clinical research services for the trial and related open-label extension. The second cap is the scope of the PPD engagement, not a second $40 million contribution. Neither is unrestricted cash for Arcturus. The company said the decision may come before the planned Phase 2 results presentation. Even if it does, public investors still need to know which costs qualify and what remains with Arcturus. July 2 Form 8-K, Item 1.01 · September 10-Q, Note 8 · November 5 Exhibit 99.1.
For a development program, the importance of in-kind contributions can exceed what immediately appears in a cash statement. They can reduce the amount a sponsor would otherwise pay, provide access to established clinical research capacity, or reduce uncertainty about who will carry out later work. They can also leave material costs on the sponsor’s side: internal oversight, portions of trials outside scope, commitments that precede reimbursement, and any activities not covered by the agreement. No separate commercial supply agreement had been executed and no amounts related to those commercial provisions had been recognized as of September 30. Conditional commercial rights should not be read as current sales or a guarantee of scale.
The Cystic Fibrosis Foundation support sits in a different accounting category. Under a September 2023 amendment, the award rose to $24.6 million from about $15.6 million, with Arcturus agreeing to incur at least $15.0 million toward work under the research plan. Arcturus says it received the full payment related to the amendment in the fourth quarter of 2023. It recognized approximately $0.6 million as an offset to expense over the first nine months of 2026 and reported a $5.756 million accrued CFF liability at September 30. The amount accrued is not an outstanding loan. It also helps explain why reported net CF program spending and gross resources dedicated to it are not interchangeable. Notes 4, 8, and 9.
Separately, the annual filing will need to reflect an acquisition closed after the end of the quarter. The September 10-Q said Arcturus was assessing whether myNEO should be accounted for as a business combination or an asset acquisition and evaluating its significance. This matters for interpreting the next report: the accounting can affect which amounts are expensed, which become assets and which future payments are recognized. It will not retrospectively transform a contingent maximum into a payment already made. The useful check is the year-end disclosure of purchase accounting, the valuation of consideration, and any material integration costs—not a presumption that the acquired capabilities have already generated a clinical asset.
Across the contracts the practical distinction is between reducing the amount a trial will cost and obtaining the evidence needed to spend confidently. Meiji’s equity can broaden management’s options. Thermo Fisher’s agreement can matter once the right activities qualify. Foundation support can offset costs for a defined development plan. The economics should be visible in different places in the filings. Summing their headline amounts as one pool of funding would obscure which resources are actually available for which stage.
12Beneficial ownership and trading liquidity
A Schedule 13G reports beneficial ownership, which can reflect voting or investment power and can be shared. Read the event date, reporting entity and basis of the percentage before comparing two numbers. Meiji’s statement relates to the November transaction. The other recent amendments relate to positions measured September 30 and use the earlier share base. They cannot be combined as if they were a single list of mutually exclusive holders using a common denominator.
| Reporting entity | Position date | Filing date | Reported shares | % of class |
|---|---|---|---|---|
| Meiji Seika Pharma | Nov. 16, 2026 | Nov. 18, 2026 | 2,466,395 | 7.88% |
| Amova Asset Management Americas | Sep. 30, 2026 | Nov. 13, 2026 | 1,689,107 | 5.9% |
| Sumitomo Mitsui Trust Group and Amova Asset Management | Sep. 30, 2026 | Oct. 29, 2026 | 1,689,107 | 5.9% |
| Federated Hermes reporting group | Sep. 30, 2026 | Oct. 7, 2026 | 1,678,069 | 5.90% |
The filings tied to Amova report overlapping interests; they should not be added together. The U.S. adviser’s amendment reports shared voting power over 1,459,991 shares and shared disposition over 1,689,107, illustrating why voting and disposition totals need not match. The Federated filing likewise reports the same underlying shares at several levels of a reporting structure. None of these entries should be treated as a proxy for the float. No new Schedule 13D appears in the company’s 2026 EDGAR filings through November 21.
Insider forms have a different purpose. Seven June 15 Form 4s report June 5 option awards of 15,000 shares underlying each option award, with code A in Table II; see the filing for director Edward W. Holmes and the same-day filing list. Chief Financial Officer Dennis Mulroy’s May 7 Form 4 likewise reports a May 1 grant of an option for 100,000 shares, also code A. Code P is a purchase, S a sale, M an exercise or conversion, and F withholding or delivery of securities for an exercise price or tax liability. The specified filings report grants, not discretionary purchases, exercises, sales, or withholding. They affect the inventory of awards, not the historical placement proceeds.
Nasdaq’s short-interest series reported 5,409,475 shares short for the October 30 settlement, with average daily volume of 734,287 shares in that series and about 7.37 days to cover. Separately, across the 15 sessions from November 2 through November 20, Nasdaq historical volume averaged about 622,830 shares per session. The November turnover figure is useful as more recent context, but it does not belong in the earlier days-to-cover ratio. A settlement series counts positions at a point in time; daily trading counts shares changing hands and can include repeated trades in the same share.
The September filing and November current reports identify Nasdaq as the exchange and disclose no listing notice in those documents. The data support a picture of ongoing trading, with short positioning large relative to ordinary turnover. That can make execution around a disclosure harder to gauge in either direction. A change in positioning might affect how abruptly the market reacts; it provides no evidence about clinical response, partner economics, or the solvency of Arcturus. The Health Score uses those separate observations as measures of trading conditions, not as a substitute for clinical diligence.
13The commercial reset and the tests that matter in 2027
KOSTAIVE has a defined regulatory history apart from Arcturus’s development programs. The European Medicines Agency’s product record shows authorization throughout the European Union on February 12, 2025 and lists Arcturus Therapeutics Europe B.V. as the marketing authorization holder. In November, Arcturus said the EU and UK authorizations had transferred from CSL Seqirus in September and October 2026, respectively, in preparation for commercial activity in 2027. In the same company update, Arcturus said commercial sales were ongoing in Japan for the 2026–2027 season. These are different jurisdictions and milestones; a transfer of the authorization holder does not quantify sales, orders, reimbursement or the cost of distribution.
The surviving Japan arrangements under the former CSL contract apply for the 2026–2027 season, which Arcturus expects to end on or around June 30, 2027. The company expects to work directly with Meiji beginning with the following season. In the interim, the February 2025 EU authorization is a product fact, the 2026 transfers are administrative and commercial facts, and 2027 commercial planning remains forward-looking. The 10-Q’s collaboration note and business update provide no basis to book a recurring revenue level from a future season. They also describe grants tied to specified activities. The grant, seasonal vaccine activity and any incremental rare-disease partnership should be analyzed as separate sources of possible cash.
The trade-off is sharper because the formerly partnered business can demand resources after the old collaboration ends. Rights that return to an issuer can have value, but they can also carry costs that previously sat elsewhere. A new distribution agreement can improve the outlook when it identifies the partner, market, and economic responsibility. A decision to retain rights may preserve more potential future revenue while requiring more spending. The public evidence to distinguish those routes is a binding agreement or actual results, not the number of territories listed in a regulatory release.
Arcturus also identified earlier-stage work in phenylketonuria and gout and described a second-half 2027 target for a phenylketonuria investigational new drug submission in the November earnings release. An IND submission, if made, is the start of a regulatory and clinical process, not a marketing application or evidence of benefit. The new opportunities compete for resources with CF, OTC deficiency and the post-CSL transition. Near-term outcomes in the lead programs should have more bearing on the allocation of capital than adding another early indication to a portfolio summary.
Three observations can narrow the uncertainty in 2027: a CF data set that distinguishes patients with complete follow-up from those who discontinue; an ARCT-2601 result with evidence attributable to that candidate and enough safety context to judge repeated use; and cash disclosures that separate funds received from services and contingent terms. Those observations answer separate questions about the medicines and the balance sheet. Agreement across all three would be materially stronger than a succession of positive headlines that each tells a different part of the story.
Until then the central question is how much decision-quality human evidence Arcturus can produce before it commits to materially higher spending. As of November, the company has contracted resources and a dated contingent financing term that investors can follow. Its operating performance over the next several quarters will be measured less by whether it restores the peak revenue of the CSL period than by whether it turns that financing flexibility into a clinical decision backed by data and leaves enough cash to act on it.
Merlintrader Health Score
Assessed November 21, 2026. The score describes operating and financing resilience over the next 12 to 18 months. It is not an investment recommendation.
3.2out of 5
Weighted calculation: 0.30 × 4.0 + 0.30 × 3.0 + 0.20 × 2.5 + 0.10 × 2.5 + 0.10 × 3.5 = 3.2/5.
ARCT red flags
- Quarterly revenue is distorted by the exit payment. Read the CSL breakdown before extrapolating the third quarter.
- The Meiji refund term has two possible settlement channels. Cash would reduce resources; equity could add shares. See the contract terms.
- CF has imaging observations but an unproven functional effect. The later exploratory comparison did not replace the original spirometry result. See the earlier study data.
- OTC tolerability matters across repeated treatment. The ARCT-810 interim disclosure includes liver enzyme elevations; ARCT-2601 still needs its own data. See the OTC evidence.
- In-kind services cannot fund any project management chooses. The Thermo Fisher terms cover qualifying work and phase-dependent commitments.
- Historical ATM inactivity is not a commitment. The issuer can change how it finances the next trial. See the share and financing disclosures.
ARCT Stock FAQ: Arcturus Therapeutics Questions Answered
When is the next ARCT stock catalyst?
On November 5, 2026, Arcturus targeted year-end 2026 for ARCT-032 Cohort 4 enrollment completion and the second quarter of 2027 for a data presentation; it did not announce exact days. The separate May 31, 2027 date is a Meiji contract deadline. Company update · Meiji 8-K.
Is Arcturus’ ARCT-2601 FDA approved?
No. The November 5, 2026 disclosure describes ARCT-2601 as investigational and sets out plans to start Phase 2 dosing in the first quarter of 2027. Management described FDA feedback from a June meeting; that feedback was not marketing approval. November 5 Exhibit 99.1.
How much cash does Arcturus have, and how long will it last?
Arcturus reported $184.817 million of cash and equivalents at September 30, 2026, excluding $2.028 million of restricted cash. In its November 5 release management estimated a runway through year-end 2028, before the November 16 placement; the 10-Q described at least 12 months under stated assumptions. 10-Q · Results release.
Is ARCT stock at risk of dilution?
Yes. On November 16, 2026, Arcturus issued 2,466,395 common shares to Meiji. The September 10-Q also describes ATM capacity and equity plans, and some contingent obligations may be eligible for share settlement. November transaction · September 10-Q.
When did Arcturus Therapeutics last report earnings?
Arcturus reported its quarter ended September 30, 2026 on November 5, 2026, with revenue of $18.297 million and a net loss of $7.414 million. The release accompanied the filing of the quarterly report. Form 10-Q · Results 8-K.
What does Arcturus Therapeutics do?
As described in its November 5, 2026 10-Q, Arcturus develops messenger RNA medicines, including investigational treatments for cystic fibrosis and ornithine transcarbamylase deficiency. It also developed the vaccine KOSTAIVE, with country-specific marketing authorizations and commercial arrangements. 10-Q business overview.
Who owns more than 5% of Arcturus stock?
Meiji reported 7.88% as of its November 16, 2026 event date. Amova-related filings reported 5.9% and the Federated Hermes group reported 5.90%, both based on September 30 positions. Related Amova filings cover overlapping shares. Meiji · Amova Americas · Federated Hermes.
How does Arcturus’ Thermo Fisher partnership support ARCT-032?
On June 26, 2026, Thermo Fisher agreed to contribute up to $40 million in qualifying clinical manufacturing services. If Arcturus advances to Phase 3, Arcturus has agreed to engage PPD for up to $40 million in qualifying research services. The agreement does not provide Arcturus with $80 million in cash or in-kind contributions. Form 8-K, Item 1.01 · 10-Q, Note 8.
Primary sources and peer-reviewed research
- SEC · September 2026 Form 10-Q, filed November 5
- SEC · June 2026 Form 10-Q, filed August 6
- SEC · 2025 Form 10-K, filed March 3, 2026
- SEC · November 5 Form 8-K, results
- SEC · November 5 Exhibit 99.1, results and pipeline
- SEC · November 16 Form 8-K, Meiji transaction terms
- SEC · November 16 Exhibit 99.1, Meiji release
- SEC · September 23 Exhibit 99.2, OTC interim release
- Arcturus investor relations · release index
- Nasdaq · ARCT short interest by settlement date
- Nasdaq · ARCT daily trading volume
- SEC · November 18 Meiji Schedule 13G
- SEC · November 13 Amova Americas Schedule 13G/A
- SEC · October 29 Sumitomo and Amova Schedule 13G/A
- SEC · October 7 Federated Hermes Schedule 13G/A
- SEC · June 15 Form 4, director option award
- SEC · May 7 Form 4, CFO option award
- SEC · Arcturus full filing index
- ClinicalTrials.gov · LunairCF (NCT06747858)
- ClinicalTrials.gov · U.S. ARCT-810 study (NCT06488313)
- ClinicalTrials.gov · separate randomized ARCT-810 study (NCT05526066)
- Arcturus · October 22, 2025 ARCT-032 interim findings
- EMA · KOSTAIVE regulatory record
- U.S. District Court, Southern District of California · November 3 order, case 3:25-cv-02494
- SEC · September 23 Exhibit 99.1, human OTC results, slides 8–11
- SEC · July 2 Form 8-K, June 26 Thermo Fisher agreement
- Middleton et al. · New England Journal of Medicine 2019 · Triple combination in F508del/minimal function
- Castellani et al. · American Journal of Respiratory and Critical Care Medicine 2026 · Selected rare CFTR variants
- Keating et al. · Lancet Respiratory Medicine 2025 · SKYLINE active comparator trials
- Rowe et al. · Journal of Cystic Fibrosis 2023 · MRT5005 study
- McNally et al. · American Journal of Respiratory and Critical Care Medicine 2023 · RECOVER
- Batshaw et al. · Molecular Genetics and Metabolism 2014 · Urea cycle disorders cohort
- Brassier et al. · Orphanet Journal of Rare Diseases 2015 · OTC deficiency outcomes
- Díaz et al. · Hepatology 2013 · Ammonia exposure and glycerol phenylbutyrate
- Berry et al. · Molecular Genetics and Metabolism 2014 · Pediatric ammonia control
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $ARCT or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



